Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Quantum BioPharma Ltd.(QNTM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for QNTM
09/24/2026: QNTM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Quantum BioPharma Ltd. is a small-cap biotechnology firm focused on the development of novel therapeutics, positioning it as a high-risk, high-reward investment within the biopharmaceutical sector. The company's strengths lie in its focused R&D strategy and ability to pivot toward high-potential therapeutic targets. Its primary growth story depends on advancing its drug pipeline through clinical trials toward regulatory approval. However, the company faces significant risks, including potential clinical failures, capital dependency, and intense competition from much larger, well-capitalized industry peers. The stock may suit growth-oriented investors with high risk tolerance who are looking for exposure to biotechnology innovation, though careful monitoring of clinical milestones and cash runway is essential.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential but with significant binary risk associated with drug development. |
| Momentum investor | Mixed fit | Fit is conditional on positive clinical data or strategic announcements driving short-term price movement. |
| Value investor | Weak fit | The lack of established earnings or cash flow makes it difficult to assess value through traditional metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on development. |
| Low-risk investor | Weak fit | High volatility and the risks associated with biotechnology development make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to sharp price fluctuations based on news regarding clinical trials. |
| Valuation risk | High | The absence of traditional earnings makes valuation highly speculative. |
| Competition risk (Biotech majors) | High | The company competes with well-funded incumbents that have deeper R&D and commercial resources. |
| Business quality | Medium | The company's success is tied to the quality of its scientific pipeline. |
| Dividend income | Low / none | Investors should not expect income from this equity. |
| Execution risk | High | The inability to successfully navigate clinical trials or secure funding is a core existential risk. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -25.51% | Avg. Invested days 12 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.72M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 230.6K shares | Beta 0.45 | 52 Weeks Range 2.07 - 19.30 | Updated Date 09/25/2026 |
52 Weeks Range 2.07 - 19.30 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.68 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Researching, testing, and developing novel therapeutics. | The company aims to profit by successfully developing new drugs that can be licensed or sold. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28.16M | Price to Sales(TTM) 91.86 |
Enterprise Value 28.16M | Price to Sales(TTM) 91.86 | ||
Enterprise Value to Revenue 98.56 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 6.43M | Shares Floating 7.63M |
Shares Outstanding 6.43M | Shares Floating 7.63M | ||
Percent Insiders 8.4 | Percent Institutions 9.61 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Quantum BioPharma Ltd.
Exchange NASDAQ | Headquarters Toronto, ON, Canada | ||
IPO Launch date 2018-06-08 | Co-Founder, CEO & Executive Non-Independent Co-Chairman Mr. Zeeshan Saeed | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.quantumbiopharma.com |
Full time employees - | Website https://www.quantumbiopharma.com | ||
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.